所有图片(1)
About This Item
经验公式（希尔记法）:
C24H26N2O4
CAS号:
分子量:
406.47
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
certified reference material
pharmaceutical secondary standard
质量水平
Agency
traceable to Ph. Eur. Y0001427
traceable to USP 1096622
API类
carvedilol
CofA
current certificate can be downloaded
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-30°C
SMILES字符串
OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC
InChI
1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
InChI key
OGHNVEJMJSYVRP-UHFFFAOYSA-N
基因信息
human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146) , ADRB1(153) , ADRB2(154) , ADRB3(155)
正在寻找类似产品? 访问 产品对比指南
一般描述
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Carvedilol is a lipophilic β1- and β2-adrenoreceptor antagonist that exhibits antioxidant and antiproliferative properties. It is prescribed as a medicine for the treatment of hypertension, stable angina pectoris, post myocardial infarction with left ventricular dysfunction and all degrees of symptomatic chronic heart failure.
Carvedilol is a lipophilic β1- and β2-adrenoreceptor antagonist that exhibits antioxidant and antiproliferative properties. It is prescribed as a medicine for the treatment of hypertension, stable angina pectoris, post myocardial infarction with left ventricular dysfunction and all degrees of symptomatic chronic heart failure.
应用
Carvedilol may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations and serum samples by various chromatography techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
生化/生理作用
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.
注意
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
分析说明
These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.
附注
To see an example of a Certificate of Analysis for this material enter LRAA9063 in the slot below. This is an example certificate only and may not be the lot that you receive.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险声明
危险分类
Aquatic Chronic 2 - STOT RE 2
靶器官
Liver,spleen,Uterus (including cervix),Adrenal gland
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Simple and accurate RP-HPLC and TLC-Densitometric methods for determination of carvedilol in pharmaceutical formulations
Abdel-Gawad FM, et al.
International Journal of Research in Pharmacy and Chemistry, 2(3), 2231-2781 (2012)
Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study
do Carmo Borges NC, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 822(1-2), 253-262 (2005)
HPLC Method Development and Validation of S (-)-Carvedilol from API and Formulations
Swetha E, et al.
American Journal of Analytical Chemistry, 6(05), 437-437 (2015)
Achiral-chiral LC/LC-FLD coupling for determination of carvedilol in plasma samples for bioequivalence purposes
Medvedovici A, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 850(1-2), 327-335 (2007)
Yanzhuo Zhang et al.
International journal of pharmaceutics, 454(1), 403-411 (2013-07-16)
The main objective of this study was to develop carboxylated ordered mesoporous carbon microparticles (c-MCMs) loaded with a poorly water-soluble drug, intended to be orally administered, able to enhance the drug loading capacity and improve the oral bioavailability. A model
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门